Source comparison
CJC-1295 No DAC 60s Age Specific Protocol: Dosing Comparison
Baseline IGF-1 <110 ng/mL (low tertile) 100 mcg per injection 3× weekly (Mon/Wed/Fri or alternate days) Evening (30 min pre-bed) + optional morning dose 130–180 ng/mL Higher frequency needed to sustain IGF-1 elevation. Monitor for joint discomfort indicating o
This comparison does not assign a generated winner or score.
- Baseline IGF-1 <110 ng/mL (low tertile)
- 100 mcg per injection
- 3× weekly (Mon/Wed/Fri or alternate days)
- Evening (30 min pre-bed) + optional morning dose
- 130–180 ng/mL
- Higher frequency needed to sustain IGF-1 elevation. Monitor for joint discomfort indicating over-response
- Baseline IGF-1 110–150 ng/mL (mid-range)
- 75–100 mcg per injection
- 2× weekly (Mon/Thu or Tue/Sat)
- Evening dose prioritised; second dose optional mid-morning
- 140–190 ng/mL
- Standard protocol for most adults in their 60s. Adjust upward only if IGF-1 remains stagnant after 4 weeks
- Baseline IGF-1 >150 ng/mL (preserved function)
- 50–75 mcg per injection
- 2× weekly
- Evening only or single morning dose on training days
- 160–200 ng/mL
- Conservative approach. Preserved pituitary function requires minimal stimulation; assess for diminishing returns before increasing dose
- Fasting glucose >100 mg/dL at baseline
- 50 mcg per injection
- Post-meal window (90 min after last meal) to avoid acute glucose spike
- 120–160 ng/mL
- Prioritise insulin sensitivity. Pair with structured carbohydrate timing and reassess glucose at 6 weeks before increasing dose